<DOC>
	<DOCNO>NCT00154375</DOCNO>
	<brief_summary>This Phase III study compare Imatinib mesylate hydroxyurea combination therapy hydroxyurea monotherapy patient temozolomide resistant progressive glioblastoma .</brief_summary>
	<brief_title>Study Imatinib Mesylate Combination With Hydroxyurea Versus Hydroxyurea Alone Oral Therapy Patients With Temozolomide Resistant Progressive Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Signed informed consent prior initiation study procedure . Patients &gt; = 18 year age . Histological confirm diagnosis glioblastoma multiforme / astrocytoma World Health Organization ( WHO ) grade IV reference pathologist Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 . Adequate hepatic , renal bone marrow function define follow : total bilirubin &lt; 1.5 x Upper Limit Normal ( ULN ) , ALT AST &lt; 2.5 x ULN , creatinine &lt; 1.5 x ULN , absolute neutrophil count &gt; 1.5 x109/L , platelet &gt; 100 x109/L hemoglobin &gt; 10 g/dL . Female patient childbearing potential negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential agree employ effective barrier method birth control throughout study , 3 month follow discontinuation study drug . Life expectancy &gt; 3 month . MRI available every 6 week disease management No intercerebral inflammation Irradiation therapy 54 62 gy finish less accord national standard Chemotherapy least 1 temozolomide contain regimen finish , establish chemotherapy regiment available progression chemotherapy 6 month follow last chemotherapy . Leucocytes &gt; 2.500/µl , control week Thrombocytes &gt; 80.000/µl , control week Ensured compliance Patients second third resection disease progression include earlier 2 week follow resection . MRI perform later 72 h post operation . If patient include later 4 week resection , new baseline MRI must perform . Female patient pregnant breastfeeding . Patients treat investigational agent ( ) within 28 day first day administration study drug . Patients uncontrolled medical disease diabetes mellitus , thyroid dysfunction , neuropsychiatric disorder , infection , angina Grade 3 4 cardiac problem define New York Heart Association Criteria . Patients malignant disorder . Patient acute know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . Patients know HIV positive ( specific test require confirmation eligibility ) . Expected incompliance accord treatment , treatment diary examination schedule Not confirm histological diagnosis glioblastoma multiforme/astrocytoma WHO grade IV Other drug potential cytostatic main side effect No inadequate chemotherapy irradiation therapy Patients without hematological recovery previous chemotherapy treat Chemotherapy within 28 day first day administration study drug . Other protocolspecific inclusion /exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Open label</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>hydroxyurea</keyword>
	<keyword>temozolomide</keyword>
	<keyword>resistant</keyword>
	<keyword>protein tyrosine kinase</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>astrocytoma</keyword>
	<keyword>brain tumor</keyword>
	<keyword>brain cancer</keyword>
</DOC>